16 participants (7 placebo, 9 semaglutide) elected not to consume at the post-treatment laboratory session Findings: These findings provide initial prospective evidence that low-dose semaglutide can reduce craving and some drinking outcomes, justifying larger clinical trials to evaluate GLP-1RAS for alcohol use disorder
Examining weight suppression as a transdiagnostic factor influencing illness trajectory in bulimic eating disorders
Clinical trials demonstrate substantial reductions in body fat, particularly visceral adipose tissue, when combined with lifestyle modifications
It reduces appetite by acting on hunger centres in the brain, slows stomach emptying so you feel full longer, improves insulin secretion, reduces glucagon production, and helps target visceral (belly) fat
Wynn TA, Chawla A, Pollard JW
Treatment with semaglutide tablets 14 mg once daily for 26 weeks resulted in a statistically significant reduction in HbA1c compared to empagliflozin 25 mg once daily (see Table 5)